Hereditary Cancer in Clinical Practice (Oct 2019)

Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report

  • Mev Dominguez-Valentin,
  • Toni T. Seppälä,
  • Julian R. Sampson,
  • Finlay Macrae,
  • Ingrid Winship,
  • D. Gareth Evans,
  • Rodney J. Scott,
  • John Burn,
  • Gabriela Möslein,
  • Inge Bernstein,
  • Kirsi Pylvänäinen,
  • Laura Renkonen-Sinisalo,
  • Anna Lepistö,
  • Annika Lindblom,
  • John-Paul Plazzer,
  • Douglas Tjandra,
  • Huw Thomas,
  • Kate Green,
  • Fiona Lalloo,
  • Emma J. Crosbie,
  • James Hill,
  • Gabriel Capella,
  • Marta Pineda,
  • Matilde Navarro,
  • Joan Brunet Vidal,
  • Karina Rønlund,
  • Randi Thyregaard Nielsen,
  • Mette Yilmaz,
  • Louise Laurberg Elvang,
  • Lior Katz,
  • Maartje Nielsen,
  • Sanne W. ten Broeke,
  • Sigve Nakken,
  • Eivind Hovig,
  • Lone Sunde,
  • Matthias Kloor,
  • Magnus v Knebel Doeberitz,
  • Aysel Ahadova,
  • Noralane Lindor,
  • Verena Steinke-Lange,
  • Elke Holinski-Feder,
  • Jukka-Pekka Mecklin,
  • Pål Møller

DOI
https://doi.org/10.1186/s13053-019-0127-3
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background We previously reported that in pathogenic mismatch repair (path_MMR) variant carriers, the incidence of colorectal cancer (CRC) was not reduced when colonoscopy was undertaken more frequently than once every 3 years, and that CRC stage and interval since last colonoscopy were not correlated. Methods The Prospective Lynch Syndrome Database (PLSD) that records outcomes of surveillance was examined to determine survival after colon cancer in relation to the time since previous colonoscopy and pathological stage. Only path_MMR variants scored by the InSiGHT variant database as class 4 or 5 (clinically actionable) were included in the analysis. Results Ninety-nine path_MMR carriers had no cancer prior to or at first colonoscopy, but subsequently developed colon cancer. Among these, 96 were 65 years of age or younger at diagnosis, and included 77 path_MLH1, 17 path_MSH2, and 2 path_MSH6 carriers. The number of cancers detected within 3.5 years after previous colonoscopy were 9, 43, 31 and 13, respectively. Of these, 2, 8, 4 and 3 were stage III, respectively, and only one stage IV (interval 2.5–3.5 years) disease. Ten-year crude survival after colon cancer were 93, 94 and 82% for stage I, II and III disease, respectively (p 3.5 years before diagnosis, was 89, 90, 90 and 92%, respectively (p = 0.91). Conclusions In path_MLH1 and path_MSH2 carriers, more advanced colon cancer stage was associated with poorer survival, whereas time since previous colonoscopy was not. Although the numbers are limited, together with our previously reported findings, these results may be in conflict with the view that follow-up of path_MMR variant carriers with colonoscopy intervals of less than 3 years provides significant benefit.

Keywords